NCT05034627View on ClinicalTrials.gov

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 9, 2022

Primary Completion Date

December 16, 2025

Study Completion Date

October 1, 2026

Conditions
Locally Advanced Pancreatic AdenocarcinomaMetastatic Pancreatic AdenocarcinomaStage II Pancreatic Cancer AJCC v8Stage IIA Pancreatic Cancer AJCC v8Stage IIB Pancreatic Cancer AJCC v8Stage III Pancreatic Cancer AJCC v8Stage IV Pancreatic Cancer AJCC v8
Interventions
PROCEDURE

Biopsy

Undergo biopsy

DRUG

Calaspargase Pegol-mknl

Given IV

DRUG

Cobimetinib

Given PO

Trial Locations (1)

97239

RECRUITING

OHSU Knight Cancer Institute, Portland

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Oregon Health and Science University

OTHER

collaborator

Genentech, Inc.

INDUSTRY

collaborator

Servier Pharmaceuticals, LLC

UNKNOWN

lead

OHSU Knight Cancer Institute

OTHER

NCT05034627 - Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer | Biotech Hunter | Biotech Hunter